ClinConnect ClinConnect Logo
Search / Trial NCT05946798

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

Launched by ANNA STANHEWICZ, PHD · Jul 7, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Gestational Diabetes Postpartum Vascular

ClinConnect Summary

This clinical trial is investigating the role of a specific enzyme called NADPH oxidase in causing problems with blood vessel function in women who have had gestational diabetes (GDM). Gestational diabetes is a type of diabetes that can occur during pregnancy. The researchers want to understand how this enzyme contributes to oxidative stress, which is an imbalance that can harm cells and tissues. They are looking for women aged 18 and older who have been pregnant in the last five years and either had gestational diabetes or do not have a history of it.

If you decide to participate, you will undergo some tests to help the researchers learn more about how the body’s blood vessels function after having gestational diabetes. However, there are some health conditions that would exclude you from joining, such as current skin diseases, using tobacco products, or having certain metabolic diseases like diabetes. This trial is currently recruiting participants, so if you meet the criteria and are interested, it could be a valuable opportunity to contribute to important research on women's health.

Gender

FEMALE

Eligibility criteria

  • INCLUSION CRITERIA:
  • 18 years or older
  • pregnant within 5 years of the study visit
  • had gestational diabetes diagnosed by their obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes.
  • or without a history of gestational diabetes
  • EXCLUSION CRITERIA:
  • skin diseases
  • current tobacco or electronic cigarette/vape pen use,
  • diagnosed or suspected hepatic or metabolic disease including diabetes,
  • statin or other cholesterol-lowering medication,
  • current antihypertensive medication,
  • history of preeclampsia or gestational hypertension,
  • current pregnancy,
  • body mass index \<18.5 kg/m2,
  • allergy to materials used during the experiment.(e.g. latex),
  • known allergies to study drugs

About Anna Stanhewicz, Phd

Dr. Anna Stanhewicz is a distinguished clinical trial sponsor with a robust background in biomedical research and a focus on innovative therapeutic interventions. Her expertise spans across cardiovascular health, metabolic disorders, and translational medicine, enabling her to effectively lead and oversee clinical studies aimed at advancing patient care. With a commitment to rigorous scientific methodology and ethical standards, Dr. Stanhewicz fosters collaborative environments that drive successful trial outcomes. Her leadership not only emphasizes the importance of patient safety and well-being but also aims to contribute valuable insights to the medical community.

Locations

Iowa City, Iowa, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported